MedTrace Logo

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT06137183 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.

Conditions

Interventions

DRUG

Vixarelimab

Vixarelimab will be administered as per the schedule specified in the respective arms.

DRUG

Placebo

Vixarelimab matching placebo will be administered as per the schedule specified in the respective arms.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trial · Genentech, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-06-16
Completion
2025-06-16
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • China
  • Czechia
  • France
  • Greece
  • Italy
  • Mexico
  • Poland
  • Serbia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137183 on ClinicalTrials.gov